
Tatva Chintan Pharma Chem Ltd. delivered exceptional second-quarter results, with profit after tax surging 116% to ₹21.5 crore compared to ₹9.9 crore in the previous year. According to reports from CNBC TV18, the company's revenue increased by 76% to ₹217 crore from ₹123 crore in the year-ago period. The strong performance was driven by robust growth despite facing challenges from rising raw material and global freight costs. As per ICICI Securities report, the company's Q2 FY27 revenue grew 75.9% YoY, supported by solid performance across segments, particularly structure directing agents.
The company's EBITDA increased 83% to ₹40.7 crore from ₹22 crore in the previous year, while operating margin expanded to 18% from 18% in the year-ago period. As reported by CNBC TV18, Tatva Chintan's EBITDA has shown consistent growth over the past six quarters, rising from ₹17 crore in Q1 FY26 to ₹40.7 crore in the current quarter. According to ICICI Securities, the brokerage highlighted that Q2 FY27 print sustained its strong Ebitda uptick, expanding 26% QoQ/83.3% YoY to ₹40.7 crore. However, EBITDA margin held at 18.7%, weighed down by rising solvent cost from supply shortages and steep freight charges.
Shares of Tatva Chintan gained up to 11% to hit an intraday high of ₹2,113.6 on Wednesday, October 17, following the strong quarterly results. According to CNBC TV18, this marked the stock's biggest single-day gain since July 20, 2026, when it had surged 20%. The stock has now given up most of those gains and is trading nearly 3% higher at ₹1,955.5. The stock has delivered impressive returns of 47% so far this year, reflecting strong investor confidence in the company's growth trajectory. Following the strong results, ICICI Securities has maintained its 'Buy' rating and revised its target price to ₹2,385 from earlier ₹1,955, implying a potential upside of 25% from current market price, valuing at 25 times Ebitda.
During the September quarter, the company faced erratic short supplies in some solvents, leading to price increases of 60% to 100%. As reported by CNBC TV18, despite healthy revenue growth in the highest margin SDA segment, these supply constraints increased overall raw material costs. The company also experienced a rampant increase in global freights, adding to operational challenges. However, ICICI Securities notes that Tatva Chintan expects margin headwinds to gradually normalise from Q3 FY27. The company continues to see growth opportunities across segments, with semiconductor chemicals emerging as a potential long-term growth driver.
The company highlighted that its newer initiatives in energy storage and agro and pharma intermediates are progressively opening up additional opportunities. According to CNBC TV18, these diversification efforts are helping the company expand its revenue streams and reduce dependence on any single product segment. The company's focus on these high-growth areas is expected to support sustained growth momentum in upcoming quarters. ICICI Securities has raised FY27E/FY28E Ebitda by 4–8% and changed its valuation methodology to EV/Ebitda (earlier P/E multiple) and rolled over valuations to Sep'28E. Work on the company's new greenfield facility is progressing as planned, providing visibility for medium-term growth.